N
NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares
$20.01
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of NewAmsterdam Pharma Company N.V. Ordinary Shares in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$2.15
P/E
—
Data as of Oct 1
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Before the open · Expected EPS: -$0.52
Nov 11
Posts
No posts about NAMS yet.
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma is a Netherlands-based biotech company that has not yet brought a drug to market. Its main effort is a pill designed to lower bad cholesterol and cut the risk of heart attacks and strokes, still moving through late-stage clinical trials. Because it has no approved product to sell, the company earns almost no revenue today and instead funds its research through cash reserves, partnership deals, and stock sales.